Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy
- 1 October 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 144 (4), 908-911
- https://doi.org/10.1016/s0022-5347(17)39620-9
Abstract
A recently synthesized .alpha.1-blocker, (R)-5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide hydrochloride (YM617), was evaluated in 270 patients with benign prostatic hypertrophy in a double-blind study. After 2 weeks on placebo the patients were assigned at random to 4 groups: group P-placebo, group L-0.1 mg, group M-0.2 mg. and group H-0.4 mg. of YM617. Comparing the placebo to the treatment period, subjective symptoms, such as nocturia and urgency, were significantly decreased in group H (p < 0.01). The sensation of incomplete voiding was significantly improved in groups M and H (p < 0.01). However, the differences among the groups were statistically insignificant. Residual urine volume was significantly decreased in groups L, M and H after instillation of saline into the bladder (p < 0.01) but not in group P. The maximum and average flow rates were significantly increased in groups L, M and H (p < 0.01) but not in group P. Average flow rate showed significant differences between groups M or H versus group P. Neither orthostatic hypotension nor a decrease in blood pressure was noted. Adverse side effects and changes in laboratory data were all slight and disappeared when the second tests were performed. In summary, the irritative and obstructive symptoms caused by benign prostatic hypertrophy were decreased and urodynamic studies were markedly improved by the .alpha.1-blocker, YM617. The drug seems to be useful in the treatment of patients with benign prostatic hypertrophy.This publication has 15 references indexed in Scilit:
- Autoradiographic Analysis of Alpha-Adrenoceptors and Muscarinic Cholinergic Receptors in the Hyperplastic Human ProstateJournal of Urology, 1989
- The Alpha Adrenergic Binding Properties of Terazosin in the Human Prostate Adenoma and Canine BrainJournal of Urology, 1988
- Identification and Characterization of Alpha 1 Adrenergic Receptors in the Canine Prostate Using [ 125 I]-HeatJournal of Urology, 1987
- Alpha 2 Adrenergic Receptors in Canine Prostate: Biochemical and Functional CorrelationsJournal of Urology, 1987
- Use of an α1-Blocker, YM-12617, in Micturition DifficultyUrologia Internationalis, 1987
- The Present Role of Alpha-Adrenergic Blockers in the Treatment of Benign Prostatic HypertrophyJournal of Urology, 1986
- A Pharmacological Study of Alpha Adrenergic Receptor Subtypes in Smooth Muscle of Human Urinary Bladder Base and Prostatic UrethraJournal of Urology, 1985
- Characterization of Alpha 1 Adrenergic Receptors in Human Benign Prostatic HyperplasiaJournal of Urology, 1984
- Effects of Prazosin in Patients with Benign Prostatic ObstructionJournal of Urology, 1983
- Alpha-Adrenergic Activity and Urethral Pressure in Prostatic Zone in Benign Prostatic HypertrophyJournal of Urology, 1982